Home » Newsletters » BioWorld Science

BioWorld Science

March 15, 2002

View Archived Issues

Orally active acetylcholinesterase and 5-HT uptake inhibitor proposed for Alzheimer's disease

Protopic cleared for launch in Europe

GK-04489, a new compound with efficacy in arterial thrombosis and cerebral ischemia

Findings presented at AAAAI meeting further support development of Genaera's mucoregulator

BIA-2-024, a new antiepileptic drug, evaluated for metabolism in animals and in vitro

NeoTherapeutics develops promising new family of antipsychotic drugs

Potent and selective integrin inhibitors synthesized at Celltech

First phase I trial of anti-HIV-1 human MAbs assessing safety and pharmacokinetics

ICAgen research leads to two new series of antiarrhythmic agents

GSK describes novel fatty acid synthase FabH inhibitors for bacterial infections

Signal discloses a novel group of JNK inhibitors for a wide range of conditions

More thrombin inhibitors in development at Merck

Antitumor activity of AN-238 against human colorectal cancers independent of p53 status

ISIS-104838 enters second phase II trial in RA

Collateral Therapeutics gains rights to EPAS1 gene

Phase I results show Product R to be safe and well tolerated

Cambrex to manufacture Bioheart's MyoCell therapy

IL-9 blockade continues to show promise for the treatment of asthma

Extended-release Zerit has similar virological activity to immediate-release drug

Risperdal approved for delaying schizophrenia relapse in U.S.

Trisenox approved in Europe for acute promyelocytic leukemia

Keryx initiates phase II dosing of KRX-101 in HIV-associated nephropathy

Third of three phase III trials under way for AC-2993 in treatment of type 2 diabetes

Bavarian Nordic reviews 2001 progress, 2002 outlook

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...